Restasis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Funding
• Alerts
• Clinical Trials
• Forums

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Condition:   Stem Cell Transplantation Interventions:   Drug: Fludarabine;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Bortezomib;   Drug: Rituximab;   Drug: Busulfan;   Drug: Cyclophosphamide (Cy);   Drug: Tacrolimus (or cyclosporine);   Drug: Mycophenolate mofetil (MMF);   Drug: Rabbit ATG Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
Condition:   Graft Versus Host Disease in Eye Interventions:   Drug: Cyclosporine;   Drug: tacrolimus Sponsor:   Peking University Third Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Condition:   Stem Cell Transplantation Interventions:   Drug: Fludarabine;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Bortezomib;   Drug: Rituximab;   Drug: Busulfan;   Drug: Cyclophosphamide (Cy);   Drug: Tacrolimus (or cyclosporine);   Drug: Mycophenolate mofetil (MMF);   Drug: Rabbit ATG Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
Condition:   Graft Versus Host Disease in Eye Interventions:   Drug: Cyclosporine;   Drug: tacrolimus Sponsor:   Peking University Third Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Condition:   Stem Cell Transplantation Interventions:   Drug: Fludarabine;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Bortezomib;   Drug: Rituximab;   Drug: Busulfan;   Drug: Cyclophosphamide (Cy);   Drug: Tacrolimus (or cyclosporine);   Drug: Mycophenolate mofetil (MMF);   Drug: Rabbit ATG Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
Condition:   Graft Versus Host Disease in Eye Interventions:   Drug: Cyclosporine;   Drug: tacrolimus Sponsor:   Peking University Third Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Condition:   Stem Cell Transplantation Interventions:   Drug: Fludarabine;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Bortezomib;   Drug: Rituximab;   Drug: Busulfan;   Drug: Cyclophosphamide (Cy);   Drug: Tacrolimus (or cyclosporine);   Drug: Mycophenolate mofetil (MMF);   Drug: Rabbit ATG Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
Condition:   Graft Versus Host Disease in Eye Interventions:   Drug: Cyclosporine;   Drug: tacrolimus Sponsor:   Peking University Third Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Condition:   Stem Cell Transplantation Interventions:   Drug: Fludarabine;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Bortezomib;   Drug: Rituximab;   Drug: Busulfan;   Drug: Cyclophosphamide (Cy);   Drug: Tacrolimus (or cyclosporine);   Drug: Mycophenolate mofetil (MMF);   Drug: Rabbit ATG Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
Condition:   Graft Versus Host Disease in Eye Interventions:   Drug: Cyclosporine;   Drug: tacrolimus Sponsor:   Peking University Third Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Condition:   Stem Cell Transplantation Interventions:   Drug: Fludarabine;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Bortezomib;   Drug: Rituximab;   Drug: Busulfan;   Drug: Cyclophosphamide (Cy);   Drug: Tacrolimus (or cyclosporine);   Drug: Mycophenolate mofetil (MMF);   Drug: Rabbit ATG Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
Condition:   Graft Versus Host Disease in Eye Interventions:   Drug: Cyclosporine;   Drug: tacrolimus Sponsor:   Peking University Third Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Condition:   Stem Cell Transplantation Interventions:   Drug: Fludarabine;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Bortezomib;   Drug: Rituximab;   Drug: Busulfan;   Drug: Cyclophosphamide (Cy);   Drug: Tacrolimus (or cyclosporine);   Drug: Mycophenolate mofetil (MMF);   Drug: Rabbit ATG Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials

Stability of Tacrolimus, Cyclosporine A, Everolimus and Sirolimus in Whole Blood Patient Samples
Condition:   Transplantation Drugs Stability Intervention:   Procedure: Blood sampling Sponsors:   Thermo Fisher Scientific Oy;   ICON plc Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 10, 2022 Category: Research Source Type: clinical trials